Role of allogeneic and autologous hematopoietic stem cell transplantation in acute myeloid leukemia

International Journal of Hematology

Volumn 72, Issue 3, 2000, Pages 280-284

  Burnett, Alan K ^a   Kell, Jonathan ^a   Rowntree, Clare ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Autologous stem cell transplantation

Indexed keywords

ACUTE DISEASE; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MYELOID LEUKEMIA; PATHOLOGY; REVIEW;

ACUTE DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034304890     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Zittoun R, Suciu S, Watson M, et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant. 1997;20:307-315.
2. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903.
3. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116-4124.
4. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukaemia: results of the Medical Research Council's 10th AML Trial (MRC AML 10). Blood. 1997;89:2311-2318.
5. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
6. Burnett AK, Goldstone AH, Milligan DW. Daunorubicin versus mitoxantrone as induction for AML in younger adults given intensive chemotherapy: preliminary results of MRC AML12 trial. Br J Haematol. 1999;105(suppl 1):67(a).
7. Rowe JM, Neuberg D, Friedenberg W. A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55 years) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group (E3993). Blood. 1998;92:313a.
8. Bishop JF, Matthews JP, Young G A, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710-1717.
9. Weick JK, Kopecky KJ, Appelbaum FR,et al. A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841-2851.
10. Bishop JF, Lowenthal PM, Joshua D, et al. Etoposide in acute non-lymphoblastic leukemia. Blood. 1990;75:27-32.
11. Yunis JJ, Brunning RD, Howe RB, Lobell M. High-resolution chromosomes as an independent prognostic indicator in adult acute non-lymphocytic leukemia. N Engl J Med. 1984;311:812-818.
12. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood. 1998;92:2322-2333.
13. van Putten WLJ, Lowenberg B. Prognostic factors in adult AML. Blood. 1997;90(suppl 10):65a.
14. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107:69-79.
15. Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091-3096.
16. Truran LN, Kell J, Nicholson D, Hoy TG, Burnett AK. Quantitative BAX expression correlates with response to treatment in AML. Blood. 1998;92:218a.
17. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.
18. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of pre- and post-remission therapy in adult acute myeloid leukemia (AML): a SWOG/ECOG Intergroup Study. Blood. 1998;92:678a.
19. Lo Coco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet. 1992;340:1437-1438.
20. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomised MRC Trial. Blood. 1999;93:4131-4143.
21. Morschhauser F, Cayuela JM, Martini S, et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. J Clin Oncol. 2000;18:788-794.
22. Robinson LG, Owen-Jones CE, Austin SJ, Mills KI, Burnett AK. Relationship between PCR status following chemotherapy and outcome in t(8;21) positive acute myeloid leukaemia [abstract]. Br J Haematol. 1999;105:67.